



# Regulatory Education for Industry (REdI): **GENERIC DRUGS FORUM**

Sheraton | Silver Spring, MD | April 22-23, 2015

## **GDUFA User Fee Payments**

**Gisa Perez, Generics Branch Chief**

Division of User Fee Management & Budget Formulation  
Office of Management  
CDER, FDA



# Overview

- **GDUFA user fees time line**
- **Facility Fees**
- **Question 38**
- **356H Form, current POC, and facility references**
- **Refund Process**
- **§ 10.75**
- **Top 10 ways to make sure your GDUFA payment goes wrong!**
- **Resources**



# GDUFA User Fees Time Line

**FY 2016 runs from Oct. 1, 2015 through Sept. 30, 2016**

**May 1, 2015**

**June 1, 2015**

**First week of  
August 2015**

**October 1,  
2015**

- **Facilities fees are due on October 1 of each year**
- **ANDA/PAS filing fee are due at the time of submission**
- **DMF fee is incurred on first reference of that DMF**
- **PET exception**
- **No small business waivers or exceptions**



# Facilities Fee

- The facility fee is incurred:
  - ✓ for those facilities referenced
  - ✓ in a pending or approved
  - ✓ generic drug submission
  - ✓ as of the fee due date

## Beware of:

- Cross over period
- Correct FEI on coversheets
- Correct business operation(s) for each FEI



## Question #38

- In the second version of the GDUFA Q&A Draft Guidance (<http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM316671.pdf>).
- This procedure allows a facility to revoke its letter of authorization for a sponsor to reference that facility.
- Notify both my office and the Office of Generic Drugs of the revocation of this authorization.



# Form 356H and its Contents

- Be sure to use the current 356H form (Exp. 12/31/17)  
(<http://www.fda.gov/downloads/aboutfda/reportsmanualsforms/forms/ucm082348.pdf>).
- Always include the current POC for the submission and the facilities.
- Keep the facilities reference up-to-date.
- Provide complete facility information (FEI, address, DUNS, etc).
- List all functions performed by each facility.



# Refund Process

## Refunds issued for

- ✓ **Payments made in error (§ 744B(m))**
  - ✓ **Must be requested within 180 days of payment**

## Note

**No refunds are issued for fee-related RTRs issued by the Office of Management**





# Refund Process, continued

## Refunds issued for:

- ✓ Refuse to Receive issued by OGD a 75% refund is issued

## Internal Process

- Refunds are normally processed 1-3 months after an RTR
  - ✓ You can request a refund via email right after you receive the RTR letter
  - ✓ If you plan to resubmit, we can hold the funds





## **§ 10.75**

- **If all else fails, and you feel the Agency has taken an adverse action in error, there is a provision in the Code of Federal Regulations for you to seek relief.**
- **21 CFR 10.75 outlines a procedure for seeking to have an Agency decision re-evaluated and, potentially, overturned.**
- **The first level of review is with the body that made the initial decision; subsequent reviews are conducted by that person's supervisor, and eventually through the Center Director to the Chief Scientist.**



# **GDUFA Payments**

## **Top 10 Ways to Ensure That Your GDUFA Payment Goes Wrong...**



## **#10: Forget to account for the wire transfer fee**

- **Some financial institutions will charge you a fee to handle a wire transfer.**
- **These fees are typically \$10 - \$35.**
- **Make sure the amount of your payment includes any wire transfer fees!**



## #9: Don't request a refund timely

- **GDUFA requires that requests for refunds be submitted (a) in writing, and (b) no later than 180 days after the payment was made.**
- **If you feel that you are going to want your money back on a payment, be sure to request a refund before the 180-day clock expires.**
- **Once that clock expires, the Agency is unable to issue a refund.**



## #8: Pay someone else

- **Checks need to be made payable to “Food and Drug Administration” or “FDA”.**
- **Checks made payable to another entity cannot be processed and will lead to delays in satisfying your user fee obligation.**



## #7: Send the payment to someone else

- Payment instructions provide an address to which payments should be sent.
- Sending payments to a different bank or lockbox will result in delays or prevent the Agency from applying your payment in a timely manner.
- <https://www.federalregister.gov/articles/2014/08/01/2014-18108/generic-drug-user-fee-abbreviated-new-drug-application-prior-approval-supplement-drug-master-file#h-14>



## **#6: Don't tell us where to apply the funds**

- **Completing the cover sheet will provide you with a Payment Identification Number (PIN).**
- **This PIN is essential to allow us to connect your payment to your obligation.**
- **Not providing this PIN will prevent us from applying the funds to the right place – meaning your obligation will not be satisfied.**





## **#5: Don't communicate with your DMF holder(s)**

- **The DMF fee is a one-time only fee, once it's paid it never has to be paid again.**
- **Once the DMF fee has been paid, and OGD has completed an initial completeness assessment, the DMF is listed on a public website.**
- **Communicate with your DMF holder to make sure you don't pay a fee that has already been paid!**



## **#4: Pay for the wrong fiscal year**

- **There is a two-month period each year when you can pay fees for either the current fiscal year or the upcoming fiscal year.**
- **It is important to select the correct fiscal year when completing the cover sheet.**
- **This applies to application, DMF and facility payments.**



## **#3: Reference the wrong cover sheet**

- **When you create a cover sheet, the PIN generated is designed to be unique.**
- **Some people re-use these numbers and wind up paying the same obligation multiple times.**
- **Wrong fiscal year.**
- **PIN for a different facility.**



## **#2: Use the form 356h incorrectly**

- **The form is updated periodically – make sure you use the current one!**
- **Include all the facility FEI numbers.**
- **Include all the DMFs referenced in the application.**
- **Specify the packaging type – not all types incur fees.**



# **#1: Don't withdraw your facility from submissions you don't support**

- **GDUFA imposes fee obligations on certain facilities that are mentioned in pending or approved generic drug submissions.**
- **Before GDUFA, sponsors would include back-up facilities in their applications.**
- **Those facilities now can owe fees even if they're not aware that they're listed in the applications.**



# Resources

- **GDUFA Q&A Guidance:**
- <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM316671.pdf>
- **CDER's Division of User Fee Management & Budget Formulation:**
  - **CDERCollections@fda.hhs.gov**
  - **301-796-7900**

# Questions?

Evaluation: [surveymonkey.com/s/GDF-D2S7](https://surveymonkey.com/s/GDF-D2S7)